Status:
RECRUITING
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Amsterdam UMC, location VUmc
Streekziekenhuis Koningin Beatrix
Conditions:
Stage III Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Comput...
Detailed Description
Stage III non-small cell lung cancer (NSCLC) patients are at high risk of developing recurrences (50-78%) during follow-up. With more effective treatments available for patients with oligometastatic d...
Eligibility Criteria
Inclusion
- Eligible for this study are patients with stage III NSCLC (8th edition TNM Classification) who (are about to) start(ed) follow-up care (which may include adjuvant treatment) at a participating hospital. Patients may already be included during their curative intent treatment. Patients enter a screening period that runs until their randomization.
- To be eligible to participate in this study, a subject must meet all of the following criteria at the timing of randomization:
- Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment
- Treated with curative intent and started follow-up care
- All adjuvant treatments are permitted as co-intervention during follow-up care
- Age 18 years or older
- ECOG Performance Status classification 0-2 at moment of inclusion
- Written and signed informed consent by the patient or patient's representative (with the understanding that consent may be withdrawn by the patient or patient's representative at any time without consequences to future medical care)
Exclusion
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Life expectancy shorter than 6 months at the end of curative intent treatment
- Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up)
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the intervention or interpretation of HRQOL or other study results.
Key Trial Info
Start Date :
March 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2029
Estimated Enrollment :
690 Patients enrolled
Trial Details
Trial ID
NCT06082492
Start Date
March 19 2024
End Date
June 1 2029
Last Update
February 5 2025
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Tergooi MC
Hilversum, Utrecht, Netherlands, 1212 VG
2
Amsterdam UMC
Amsterdam, Netherlands
3
Antoni van Leeuwenhoek/Nederlands Kanker Instituut
Amsterdam, Netherlands
4
OLVG
Amsterdam, Netherlands